ArticleInternational journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics2026
Revisiting intraperitoneal chemotherapy for advanced high-grade serous ovarian cancer.
Article in International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Revisiting intraperitoneal chemotherapy for advanced high-grade serous ovarian cancer.International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo compare overall survival (OS) in patients with high-grade serous ovarian cancer (HGSOC) treated with intraperitoneal (IP) chemotherapy versus intravenous (IV) chemotherapy.
methodsA retrospective study of Stage III HGSOC with optimal primary cytoreduction during 2007-2019, followed by adjuvant IP or IV chemotherapy.
resultsOverall, 54 patients were included, 23 (43%) treated by IP and 31 (57%) by IV chemotherapy. Median progression-free survival (PFS) in the IP group was 39 months (95% confidence interval [CI] 34-44 months) versus 23 months (95% CI 18-28 months) in the IV group (P = 0.294). The IP chemotherapy had superior OS compared with IV chemotherapy, with median OS not reached, versus 76 months (95% CI 37-115 months) for the IV group (P = 0.075, hazard ratio 0.45, 95% CI 0.18-1.10). At 72 months, OS was 82% for the IP group versus 53% in the IV group. In a sensitivity analysis for Stage IIIc patients only (n = 39), the median OS was 130 months (95% CI 86-174 months) in the IP group, compared with 56 months (95% CI 35-76 months) for the IV group (P = 0.152). Toxicity profiles were similar in both groups, with no Grade ≥3 toxicity.
conclusionStage III HGSOC patients treated with IP chemotherapy had significantly longer OS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.